If you are interested to learn more on Pepticom’s AI peptide design & discovery technology, please contact Shoshi.Keynan@wordpress-544837-1818586.cloudwaysapps.com
In the news: https://www.kan.org.il/Item/?itemId=69208
to identify novel inhibitors that can fight the COVID19. We are looking for partners to validate and develop these peptide drug candidates. For more information: firstname.lastname@example.org
https://www.israel21c.org/30-israeli-medical-tech-solutions-to-help-fight-coronavirus/ For more information : Shoshi.Keynan@wordpress-544837-1818586.cloudwaysapps.com
Meet us and learn how Pepticom’s AI peptide design platform can augment your drug discovery process. For more information: email@example.com
Pepticom’s AI peptide design platform as part of “Lead Identification” in the drug discovery ecosystem
Dr. Immanuel Lerner, Pepticom’s CEO, will present at “DISCOVERY on TARGET” Conference in Boston (September 25-28).
Dr. Lerner will discuss Pepticom’s exciting design work on TLR4 activators in “the Cyclic Peptide Design Challenges” session.
The talk will take place on September 24 at 13:25.
Pepticom is pleased to announce that Pierre Riviere, Ph.D., has joined the company’s Scientific Advisory Board to advise Pepticom on its peptide therapeutics strategy, programs and business.
Dr. Riviere has over 25 years of biopharmaceutical industry experience with R&D leadership roles in target and drug discovery, nonclinical and early-stage clinical development. He is a recognized expert in peptide therapeutics with both established peptide modalities and emerging novel peptide technologies. Dr. Riviere is Founder and CEO of Peptide Logic, a San Diego-based biotech […]
For more information: firstname.lastname@example.org.